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Carbohydrates play a pivotal role in intercellular communication
processes. In particular, glycan antigens are key for sustaining
homeostasis, helping leukocytes to distinguish damaged tissues
and invading pathogens from healthy tissues. From a structural
perspective, this cross-talk is fairly complex, and multiple
membrane proteins guide these recognition processes, includ-
ing lectins and Toll-like receptors. Since the beginning of this
century, lectins have become potential targets for therapeutics
for controlling and/or avoiding the progression of pathologies
derived from an incorrect immune outcome, including infec-
tious processes, cancer, or autoimmune diseases. Therefore, a
detailed knowledge of these receptors is mandatory for the
development of specific treatments. In this review, we summa-
rize the current knowledge about four key C-type lectins whose
importance has been steadily growing in recent years, focusing
in particular on how glycan recognition takes place at the
molecular level, but also looking at recent progresses in the
quest for therapeutics.
1. Introduction
The term “lectin” was firstly coined in 1954 and, since 1972, it
has been systematically used to refer to all those known and
newly discovered proteins and glycoproteins which have the
ability to interact with carbohydrates.[1] Lectins are ubiquitous in
nature, and are found in microorganisms, plants and animals at
different cellular locations. They function as fundamental
information mediators in a wide variety of molecular recog-
nition processes, interacting with specific carbohydrate epito-
pes found on endogenous or exogenous oligosaccharides,
glycoproteins and glycolipids, without modifying them (non-
enzymatic). It is worth noting that their heterogeneity in many
aspects, including their function, structure, specificity, cellular
location and phylogenetic distribution makes it difficult to
establish general classification criteria. For instance, in some
cases, plant lectins have been typically subdivided into groups
according to their distribution among similar species and
common structural features: monocot mannose-binding lectins
(MMBL), jacalin-related lectins, legume lectins, chitin-binding
lectins (hevein domains), etc.[2a] However, a strictly structural
classification has been also applied in other cases. In Animalia,
there are different categories defined according to both
characteristic structural signatures and also their specific
physiological roles and subcellular location (Figure 1).[2b,c] As
examples, galectins orchestrate multiple immunological re-
sponses, chiefly participating in glycan crosslinking at the
extracellular matrix;[3] L-type lectins are located in the lumen of
the endoplasmic reticulum and Golgi, where they take part in
trafficking and sorting of maturing proteins;[4] and siglecs are
distributed on the cell surface and mediate cell-cell adhesion
processes by interacting with endogenous sialic acid residues.[5]
Among animal lectins, C-type lectin receptors (CLRs) are
particularly important in immunity, as most of them are
expressed by different leukocytes and play a great variety of
roles in host defense and maintenance of homeostasis,
including cell-cell and host-pathogen adhesion, antigen uptake
and complement activation.[6] From a structural perspective, all
these lectins contain one or more carbohydrate recognition
domains which share a series of common structural elements
highly conserved among species (Figure 2).[6,7] The most
important one is the presence of a calcium ion at the binding
site, which is mandatory for the sugar interaction (calcium-
dependent binding, “C-type”). Paradoxically, the C-type super-
family currently includes other members with the ability to
target carbohydrates without the assistance of calcium ions,[8]
and even lectins whose substrates are proteins or lipids.[9]
Nevertheless, the term C-type lectin has been maintained due
to the high structural similarity of these CRDs with the canonical
ones (Figure 2B). Other authors have simply proposed to use
the term C-type lectin-like domain (CTLD) as generic name for
C-type CRDs.[7a,10]
As defining structural elements, all CTLDs present a central
core essentially consisting of six to seven β-strands organized
into two β-sheets and flanked by two α-helices.[11] Up to four
calcium sites have been described that may be occupied or not
depending on the particular amino acid sequence (Figure
2B).[7a,11] In canonical CTLDs, calcium site 2 is always occupied as
it is the locus for sugar binding. This calcium site is composed
of residues from the β4-strand and the opposite loop. Note,
some residues participating in the metal coordination sphere
are well conserved, namely, the WND motif on the β4-strand
and the EPN/QPD motif at the loop (Figure 2C). Interestingly,
the central proline in the latter case displays a cis conformation
in most of cases. Historically, the EPN and QPD protein motifs
have been respectively associated to mannose-binding and
galactose-binding specificities, although the current knowledge
has evidenced that these specificities are wider (roughly, EPN
for Man/Fuc/Glc and QPD for Gal/GalNAc).[10–12] Regarding the
recognition of sugars, the monosaccharide itself also coordi-
nates the calcium ion through two vicinal hydroxy groups to
establish the primary interaction. Typically, this interaction is
fairly weak (in the millimolar range), although higher affinities
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result from additional contacts beyond the conserved residues
at the secondary sites and from the multivalent architecture
presentation of the lectin, which can lead to the generation of
sugar-lectin clusters.
The C-type lectin superfamily is subdivided in at least 16
groups, considering other structural aspects and differences
related to their CTLD organization and other protein domains,
as well as their cell location and roles (Figures 1 and 2A).[7b,10]
Over the last decades, many CLRs have been discovered to act
as central mediators in the dissemination and survival of many
pathogens causing infections, as well as in the development
and progression of certain cancer types and autoimmune
diseases through the recognition of self-glycans. As a result,
these lectins have become potential targets to fight high
mortality worldwide diseases such as those caused by Mycobac-
terium tuberculosis, human immunodeficiency virus (HIV), Ebola
virus (EBOV), severe acute respiratory syndrome coronavirus
(SARS-CoV), or cancer and diabetes. It is worth noting that
many of these examples involve CLRs from antigen presenting
cells such as dendritic cells (DCs) and macrophages (MΦ), which
are key in innate immunity and subsequent guiding of the
adaptive response. As examples, soluble collectins (group III)
like mannose binding lectin (MBL) and surfactant protein A (SP-
A) may be implicated in autoimmune disorders, such as allergy
or diabetes.[13,14] Selectins (group IV) are fundamental in
leukocyte trafficking and the acquisition of immunological
memory,[15] but have been also described to facilitate lymphatic
metastasis.[16,17] The dectin-1 cluster (group V) includes receptors
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such as myeloid inhibitory C-type lectin-like (MICL), lectin-like
oxidized LDL receptor-1 (LOX-1), macrophage antigen H (CLEC-
12B or MAH), and the proper dectin-1, whose implication in
different diseases (leukemia, keratitis, rheumatoid arthritis,
ulcerative colitis…) has been recently reviewed.[18]
Group II is very varied and includes many transmembrane
DC- and MΦ-related CLRs that have been demonstrated to be
also relevant in development and progression of different
diseases. Some of them, like macrophage-inducible C-type
lectin (Mincle) or dectin-2, have been recently reviewed[19,20,21]
and are progressively gaining relevance in the therapeutic field
due to their implication in immune suppression against
Leishmania major and Fonsecaea spp., and autoimmune
pathologies as atherosclerosis or arthritis.[22] Others, like the
dendritic cell immunoreceptor (DCIR) or macrophage C-type
lectin (MCL), are still under study as they could be targets of
interest for certain diseases as well.[23] Herein, we provide a
detailed picture of the current knowledge on the molecular
recognition features of four of the most thoroughly studied
CLRs from group II for the last 20 years, namely DC-SIGN,
Langerin, MGL and LSECtin (Table 1).
2. DC-SIGN
Dendritic cell-specific ICAM-3-grabbing non-integrin, abbrevi-
ated as DC-SIGN (CD209), is undoubtedly one of the most
studied CLRs over the last two decades. This protein is mainly
expressed in immature dendritic cells (DCs) from dermis, lymph
nodes and tonsils,[24] and belongs to the heterogeneous group
of ASGPR-related and endocytic DC membrane receptors,[7]
playing essential roles in innate immunity.[25] It was first
described in the early nineties,[26] but became a target of great
interest after its direct implication in HIV infectivity was
uncovered.[27] The HIV viral particles interact with DC-SIGN,
which promotes their internalization assisted by LPS1 to guide
its further degradation at lysosomal compartments.[28] Alterna-
tively, the virus is able to establish a complex interplay between
some DC co-receptors and its own glycoproteins, particularly
gp120, eventually impairing DC activity in a DC-SIGN-depend-
ent manner to enhance its proliferation.[29,30] In this regard, HIV
is also known to use DCs as vehicles to infect T cells,[31]
increasing DC-SIGN expression and CD4 targeting.[32] After DC-
SIGN recognition, the viral particles may be also shuttled to
Figure 1. General classification of animal lectins.[2b,c] The 16 groups of C-type lectins are on the right.[7,10]






identity [%] for the CRD[b]
Reported 3D-structures by X-ray crystallography or cryoEM
DC-SIGN (tetramer) Man, Fuc, High Man N-glycans (in-
ner Man), Le-type, ABO antigens
SIGNR1-SIGNR5 (65–70%),
SIGNR6-SIGNR8
1K9I, 2XR5, 2XR6, 1SL4, 1SL5, 2IT5, 2IT6, 6GHV, 2B6B (cryoEM)
langerin (trimer) Man, Fucα1-2, GlcNAc, 6SGal, High
Man N-glycans (outer Man), GAGs
langerin (77%) 3C22, 5G6U, 3KQG, 3P7F, 3P7G, 3P7H, 4N32, 4N33, 4N34,
4N35, 4N36, 4N37, 4N38, 3P5D, 3P5E, 3P5F, 3P5G, 3P5H, 3P5I
MGL (trimer) terminal GalNAc MGL1-MGL2 (64–68%) n.a.
LSECtin (dimer)[a] LSECtin (71%) n.a.
[a] Also tetramer, although in low percentage. [b] Alignments performed with BLAST, using as queries the CRD segments of UniProtKB entries Q9NNX6 (DC-
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low-pH endosomes, where they can survive for prolonged
periods of time without replication.[33] Moreover, they can
trigger infection of DCs themselves via simultaneous cross-talk
through DC-SIGN and Toll-like receptor 8,[34] and eventually
induce cell apoptosis.[35]
Besides HIV, this C-type lectin has been proved to be a
crucial anchor in the development of multiple pathogen
diseases, what has enormously increased its general interest as
a therapeutic target. Some of those pathogens, such as Ebola[36]
and dengue,[37,38] are still currently important health risks and
hence have been investigated to a greater extent. Ebola virus
internalization can be driven by either DC-SIGN or L-SIGN (the
liver/lymph node-specific homologue of DC-SIGN),[39] and sub-
sequent research have unveiled further details about the entry
routes triggered by this pathogen.[40,41] The interaction of
dengue virus with DC-SIGN has been thoroughly described at
the molecular level by cryoEM.[42] Apart from these, DC-SIGN has
also been described to take part in other viral infections
including hCMV,[43] hepatitis C virus,[44,45] KSHV,[46] phlebovirus,[47]
measles,[48] and SARS-CoV.[50] It has been recognized that some
coronaviruses bind to the ACE2 receptors located on alveolar
cell membranes to initiate infectious processes.[49] In addition,
SARS-CoV was already known to use DC-SIGN for infecting DCs
and enhance viral transmission as well.[50] Besides ACE2, and
given the current context of COVID-19 outbreak, DC-SIGN and
other lectin receptors are under intense research to understand
their possible roles in infectivity and viral spread of the novel
SARS-CoV-2, which is now causing a worldwide pandemic.[51] A
recent work points to a relationship between the levels of DC-
SIGN, L-SIGN and ACE2 expression of the host and the infection
risk, concluding that DC-SIGN, in particular, is expressed at
higher levels in Caucasian elder people (above 60) and in lungs
from smokers, especially former smokers.[52]
Aside from viruses, DC-SIGN also participates in bacterial
and fungal infections.[53,54] Similar to HIV, Mycobacteria use DC-
SIGN as attachment point[55] and modulate DC functions
through several co-receptors.[56] As a result, the bacteria
interfere with the normal production of cytokines and the
phagocytic activity,[57] hampering DC maturation and blocking
protective immune pathways.[58] In regard to fungi species,
Candida albicans is the most studied one.[54,59] At a cellular level,
it may use several different CLRs for holding on to the cell
membrane, including DC-SIGN.[60,61] In all these cases, the DC-
SIGN counterparts are exposed mannose-containing biopoly-
mers including glycoproteins and glycolipids.[62] Besides Man,
DC-SIGN also recognizes fucose (Fuc),[63] a common sugar
present in endogenous glycan motifs such as blood group
(ABO) and Lewis-type antigens.[64] DC-SIGN recognition of these
sugars (Man, Fuc) is calcium-dependent and takes place
similarly, exhibiting low millimolar affinities. However, from the
biological perspective, each sugar drives the immune response
to a different outcome.[65] Thus, as exemplified above, Man-
targeting is usually mediated by DC-SIGN and assisted by Toll-
like receptors, among others, which jointly stimulate secretion
of pro-inflammatory cytokines.[66] In contrast, Fuc-mediated
binding leads to the recognition of self-glycoproteins like ICAM-
2[67] or ICAM-3,[68] thereby aiding DCs to move, communicate
and/or guide the actions of other cells.[69] In some cases, DC-
SIGN also triggers an immunological response through Fuc
recognition, for instance, in bacterial infections initiated by
Helicobacter pylori[70] or in parasitic infections provoked by
Schistosoma mansoni.[71] These organisms display surface glycan
motifs very similar or identical to those found on mammalian
cells (as LDNF or LeX),[72] exerting modulating effects that allow
them to shape the immune response.[73] Similarly, proper DC
activation can be impaired by Fuc-containing self-motifs,
Figure 2. Characteristic structural features of C-type lectins. A) Cartoon
representation of five representative CLRs belonging to five different C-type
lectin groups (II, III, IV, V and VI).[6,10] B) Structural comparison between the
CRDs of the same five lectins: human langerin (PDB ID: 5G6U), human
surfactant protein D (PDB ID: 4E52), human L-selectin (PDB ID: 3CFW), murine
dectin-1 (PDB ID: 2CL8), and human macrophage mannose receptor 1 (CRD2,
PDB ID: 5XTS). Calcium ions are depicted in each case. C) Common structural
motifs present in the CTLD fold (model: DC-SIGN CRD, PDB ID: 1SL5). Right:
the main secondary structure elements; left: typical conserved residues
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allowing malignant cells to escape from immune detection as
occurred through Lewis-type antigens in colorectal cancer.[206]
Altered fucosylation patterns have been also ascribed to an
incorrect DC-SIGN-mediated regulation of the immune outcome
in certain cases, for instance contributing to brain damage in
multiple sclerosis (MS).[231]
As other related lectins, DC-SIGN displays an extracellular
domain (ECD) divided into the CRD and the neck region.[7b] The
latter is composed of eight amino acid repeats, seven of them
comprising 23 residues and an extra truncated repeat (15
residues) at the N terminus.[74] The neck domains trigger the
assembly of four protomers into a highly-structured coiled-coil
tetramer. Notably, tetramerization is exclusively neck-depend-
ent and requires at least the presence of six repeats to maintain
it as the dominant oligomeric species.[75] Although there are no
crystallographic models describing the full ECD, partial X-ray
data, SAXS and computational modeling have allowed depict-
ing suitable arrangements for the tetramer. In these models,
each repeat forms an α-helix which places its six aliphatic
residues facing the inner core, supporting the hydrophobic
packing of four α-helix coils. Moreover, pH-driven destabiliza-
tion of the coiled-coil stalk suggests that there could be also
electrostatic interactions involved in tetramer stability.[76] Ac-
cording to modeling data, the four CRDs can display two types
of spatial arrangements, referred to as “open flower” and
“closed flower”. Crystallographic data obtained for the close
homologue L-SIGN[74] have pointed towards an “open flower”
disposition, in which the last neck repeat forces the CRDs to
adopt a configuration of a dimer of dimers.[76,77] In contrast,
SAXS data better support a preferential “closed flower” for DC-
SIGN. Experimental evidences additionally agree that CRDs may
freely modify their relative conformation to dock multivalent
complex glycans, resulting in the transmission of these
conformational changes to the neck regions.[78] Overall, a
unique 3D-model might not fully explain the dynamic observa-
tions, and moreover, both flexible CRDs and binding-mediated
neck changes fit with the high avidity noticed for this lectin[79]
and the role of the neck regions in antigen endocytosis
pathways.[80] Finally, the neck domains take part in the
association of multiple tetramers at the cell surface, creating
dispersed nanoclusters that are thought to magnify cell
recognition of the pathogenic entity.[81]
Regarding its sugar recognition profile, DC-SIGN is the
paradigmatic case of ligand binding promiscuity. Its primary
calcium site is surrounded by a relatively uniform flat surface,
very exposed to the solvent and with few protruding side
chains. This particular geometry easily enables the accommoda-
tion of a wide variety of glycans. As mentioned above, DC-SIGN
preferentially interacts with Man and Fuc, but the plasticity of
the sugar interaction also makes possible the coordination to
Glc, GlcNAc and ManNAc.[63] The recognition profile of its close
homologue L-SIGN is substantially similar, except for few
differences regarding the interaction with Lewis-type
antigens.[63,85,100] Even Gal is recognized by both lectins as well,
although the dissociation constant is substantially weaker.
According to recent reports using fluorinated analogues, sugar
positions 3 and 4 seem to be essential for binding of Fuc, Glc
and Gal to DC-SIGN, whereas only position 3 is important in
Man, as it can tolerate fluorination at C4.[82,83] Indeed, Man has
been demonstrated to generate up to three different binding
poses, two of them through hydroxy groups OH3 and OH4, and
an additional one, very stable, through hydroxy groups OH2
and OH3.[82] In natural highly-mannosylated glycans, the outer
Man residues are often α1-2-linked to the previous sugars,
disabling recognition mediated by the OH2-OH3 pair. Other-
wise, the other two binding poses have been identified in
crystallographic structures, and actually co-exist in solution for
the Manα1-2Man fragment.[79,84] In larger glycans, the presence
of multiple surrounding sugars gives rise to other stabilizing
interactions that are typically more favored in one of the
possible binding modes. Hence, in most cases, X-ray sugar-
lectin complexes show that the primary Man epitope adopts
the same orientation, with its OH2 group close to the long loop
and its OH6 next to Val351.[79,85,86] Remarkably, in all cases, these
structures always display an inner α1-3-linked Man moiety at
the calcium site, placing the nonreducing end on top of the
long loop, while the upstream scaffold is perfectly accommo-
dated at the secondary site, flanking Phe313 (Figure 3A and B).
Besides α1-3-linked Man moieties, DC-SIGN targets α1-2-linked
and α1-6-linked Man residues as well, always located at inner
positions of the Man9 scaffold. The two first types are the
preferred ones, whereas the recognition mediated by α1-6-
linked mannoses seems to be weaker.[87,88] These observations
highlight that interactions provided by outer mannoses might
not be so relevant, likely due to the lack of important secondary
noncovalent contacts. Therefore, the resulting binding strength
is often mainly determined by the number of available inner
Man units, justifying in many cases the enhanced affinities
noticed for high-Man ligands, probably as a result of “statistical
rebinding” effects.[89,90]
Figure 3. Binding poses experimentally described for the DC-SIGN CRD and
four typical mannosylated and fucosylated oligosaccharides. Structures A, B
and D have been solved by X-ray crystallography. Model C is a representative
structure obtained by MD and supported by NMR data. Sugars are colored
as follows: Man: green, Fuc: magenta, Gal: yellow, Glc: blue. Residues F313,
V351 and K368 are shown as sticks in all cases. A) Man4 (PDB ID: 1SL4). B)
GlcNAc2Man3 (PDB ID: 1K9I). C) Blood group A type VI.
[83] D) Lacto-N-
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The scenario completely changes when it comes to complex
multi-antennary glycans decorated with other sugars, usually
Glc, Gal and sialic acid. Of note, the Man9GlcNAc2 undecasac-
charide has two inner Man3 cores, but only the α-linked one
can establish noticeable interactions with DC-SIGN.[85] Interest-
ingly, the GlcNAc2Man3GlcNAc2 heptasaccharide is recognized,
and the smaller GlcNAc2Man3 fragment has been actually
crystallized and analyzed (Figure 3B),[86,91] thus suggesting that
the two nonreducing GlcNAc moieties might exert a stronger
positive effect in the recognition, or at least compensate the
unfavorable accommodation of the β-Man residue. As noted,
the interplay existing between both stabilizing interactions and
steric effects eventually determines the absence or presence of
binding. Recent reports have thoroughly screened these effects
making use of large glycan arrays, evidencing striking affinity
changes sometimes arising from remote chemical
modifications.[91–93] As examples, the presence of terminal
sialylation completely abrogates recognition,[92] as well as the
elongation of the GlcNAc2Man3GlcNAc2 scaffold with Galβ1-4,
although the negative effect is asymmetric, given that the
presence of one unique Gal moiety at the α1-6 branch still
permits a weak binding (Figure 4, left).[91,93] Similarly, bisecting
residues and double core fucosylation at the reducing end of
the chitobiose disaccharide also produce an affinity loss in
general. Instead, the attachment of more nonreducing Man or
GlcNAc residues tends to enhance DC-SIGN recognition in many
cases, but the observed affinity highly depends on the overall
glycan geometry. Ligand presentation is thus a crucial aspect
underlying the suitable recognition of complex glycans archi-
tectures in in vitro assays and this is also reflected in the
biological responses.[94] Thus, despite Candida albicans exhibit-
ing several classes of complex mannans (N-linked, O-linked,
phospho-Man), DC targeting is essentially supported by N-
glycans, although phosphomannans might be also indirectly
involved in conformational modulation of the N-glycan
part.[62,95] Alternatively, Mycobacterium species are differently
recognized depending on the presence and distribution of Man
caps in their lipoarabinomannans.[96]
DC-SIGN interaction with Fuc-containing oligosaccharides
has been intensely studied as well. Similarly, glycan array
studies have provided a great amount of information about
those geometrical aspects governing binding preferences.
However, these results may sometimes result confusing, as
there is still not enough structural data to clarify discrepant
affinities from a solid molecular basis. In turn, such details are
useful since Fuc, as Man, may be analogously exploited in the
development of sugar mimetics.[97] In general terms, DC-SIGN is
able to recognize an extensive plethora of Fuc-containing
antigens, including the Lewis-type motifs (LeA, LeB, LeX, LeY) and
blood group determinants (A, B, H).[89,90,98] Lewis-type and ABO
antigens differ from each other in the sugar composition and
the configuration of the glycosidic linkages. Interestingly, at
molecular level, both LeX and blood group antigens have been
found to target the calcium site in the same way. In both cases,
the Fuc moiety coordinates the metal ion by means of OH3 and
OH4 groups, creating a very stable hydrophobic contact with
the nearby Val351 residue (H1 and H2; Figure 3C and D).
However, the other neighboring sugars play different roles in
each case. In the LeX-DC-SIGN complex, the nonreducing Gal is
accommodated at the secondary site, providing noncovalent
interactions close to Phe313.[85,99] Moreover, the central GlcNAc
also establishes an aliphatic interaction with Val351. In contrast,
for the blood groups, the nonreducing Gal/GalNAc moiety
packs against the aliphatic Val351 side chain along with Fuc,
enhancing the hydrophobic interaction with this protein
residue.[83] It is worth mentioning the role that Val351 has in
DC-SIGN selectivity towards fucosylated antigens. When this
side chain is removed (V351G) or its aliphatic nature is changed
(V351S), Man-mediated binding still occurs, whereas Fuc-
mediated binding substantially worsens.[100] In fact, L-SIGN
possesses a polar serine side chain (S363) at the equivalent
position and hence, a recognition profile very similar to the
V351S mutant of DC-SIGN: it cannot recognize LeX and LeY
structures, while binding of the LeA and LeB analogues is still
present, although rather weak.[85,100] In any case, studies with LeX
mimetics have also highlight the notable contribution of
secondary contacts around Phe313 for generating stable
complexes with DC-SIGN.[97,101]
Taking as a reference the models commented above, some
data from arrays may have a partial explanation, whereas other
observations remain neither clarified nor supported at all, for
which specific structural studies are still necessary. For instance,
the recognition of LDNF or LeY can be accounted for on the
basis that both ligands can be superimposed on the LeX
scaffold, such that their particular structural differences do not
preclude the described binding pose (Figure 4, right).[89,102]
Analogously, terminal sialylation (sialyl-LeX, sialyl-LeA) almost
abrogates binding,[98] but the reason is not fully understood
yet.[103] Finally, this issue also extends to multivalent presenta-
tions: the effect of various Fuc epitopes in the same
oligosaccharide is usually rather unpredictable. In general,
Lewis-type repeats exhibit increased affinities (statistical rebind-
ing), but not all the Fuc residues equally sustain the binding. In
the same line, the LeB and LeY antigens display higher
potencies, suggesting that both fucoses likely participate in the
Figure 4. Representative Man- and Fuc-containing epitopes and their
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recognition event.[89] In contrast, difucosylated LDN-DF antigens
from S. mansoni have been reported to be poorly recognized by
DC-SIGN (Figure 4, right).[71a] All these cases underline the
enormous importance of undertaking detailed structural studies
to unveil the fine details that modulate ligand presentation. As
a proof-of-concept, in the structural study with blood antigens,
the fine selectivity of DC-SIGN towards the B antigen has been
found to arise from a slight rebinding effect originated by the
existence of a minor binding pose, in which sugar attachment is
Gal-driven. Fittingly, the same binding mode is not possible for
the A antigen, whose terminal GalNAc cannot directly coor-
dinate the calcium ion in any way, as demonstrated by STD
NMR experiments.[83]
Over the years, the relevance of sugars in pathogen
infections, autoimmune diseases, and cancer has been pro-
gressively unraveled, and lectin targeting has become an
imperative strategy for the development of therapeutics, along
with anti-glycan vaccines.[104] Consequently, the increasing
amount of structural information on DC-SIGN and its biological
relevance have remarkably encouraged the design of specific
ligands with increased potencies. In this regard, most of
research efforts have been focused on exploiting the Man
scaffold for either improving or creating new secondary
interactions, and also on displaying them in a multivalent
fashion.[105] The paradigmatic case is the Manα1-2Man disac-
charide, whose binding modes have been exhaustively de-
scribed, as mentioned above. Over the last 15 years, sequential
modifications have been stepwise introduced in both Man
moieties, leading to compounds with affinities two-three orders
of magnitude higher (<100 μM) and total selectivity for DC-
SIGN (disabling langerin recognition; Figure 5). To note, the
substitution of the reducing pyranose by a cyclohexane ring
already produces a slight improvement, especially with respect
to drug-like properties.[106] Such a structure could be anticipated
to bind through the outer Man, mimicking the minor mode
described for Manα1-2Man,[107] but X-ray and NMR data
interestingly supported the opposite orientation, in which the
“reducing” aliphatic ring is located on top of Val351.[108]
Following these observations, the subsequent chemical mod-
ifications were placed to increase the ligand contacts with the
long loop[109] and with the secondary site (Phe313), by adding
molecular fragments at C2 or C6 of the nonreducing Man.[110,111]
In addition, these modifications also take advantage of the
shallower and more acidic binding area of DC-SIGN to hinder
langerin recognition, thereby enhancing DC-SIGN selectivity.[111]
The elongation of the mannobioside with a third reducing Man
Figure 5. Synthetic modifications progressively introduced in the Manα1-2Man scaffold in order to increase receptor affinity and DC-SIGN selectivity over
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improves the affinity as well, although the binding pose and
contacts were found to be identical to those for the
mannobiose analogue as revealed by X-ray crystallography.[112]
This is a fairly particular case, as this ligand displays two
available Man residues and hence its higher affinity expectedly
arises from multiple binding (Figure 5, bottom). Indeed, the
observed STD NMR data can only be explained by considering
two binding modes, being the major one that observed in the
crystal structure.[113] Hydrodynamic measurements showed how-
ever that the important gain in affinity arises from the ability of
the mannotriose moiety to bridge two ECDs in solution
(“receptor clustering”).[112] Overall, the cyclohexane moiety al-
ways maintains the key Man residue coordinated in the same
orientation, underlining that the alternative one might be
unfavorable or not stable enough. Conversely, the alternative
orientation has been achieved by changing the aliphatic ring by
more flexible functionalized polar glycerol chains, successfully
enabling secondary van der Waals contacts at the proximal β-
sheet.[114] Notably, the incorporation of naphtyl and phenyl
moieties allows efficient hydrophobic interactions with Phe313,
substantially lowering the dissociation constants (low μM).
As C-type lectins are intrinsically weak receptors, the most
evident way to exponentially raise the inhibitory potencies
implies using multivalent scaffolds.[115] For DC-SIGN in particular,
this has been also a field of intense research. Apart, the efficient
exploitation of multivalent interactions requires controlling
several complex factors operating at once, such as the nature of
the ligand, its individual presentation or the spatial distribution
of epitopes throughout the multivalent platform (ligand
density). Structures with multiple exposed sugar units can
compete with natural glycans, even using the simple Man as
single epitope (Table 2). Thus, dendrons carrying few tens of
mannoses can already inhibit viral infections with IC50 values in
the low-micromolar range.[116] The replacement of Man by
better epitopes, for instance Manα1-2Man, in principle aids to
enhance potencies as well.[117,118] In this line, the aforementioned
mimetics have also proven to be effective for inhibition of HIV
and dengue infections when conjugated to dendrimer-like
structures, exhibiting low-micromolar IC50 as well as improved
drug-like properties (low cytotoxicity, selectivity against
langerin).[112,119] It is worth mentioning that the ligand presenta-
tion always plays the dominant role: in some cases, affinity
changes have been no longer noticed when increasing the
dendrimer generation, indicating that the maximum effective
ligand density on the surface has been already reached.[117,120]
Man-coated gold nanoparticles are an illustrative example of
such an effect, since the best potencies often correspond to
intermediate percentages of epitope occupancy.[118,121] In these
cases, linear scaffolds such as synthetic glycopolymers[122] or
DNA/RNA templates[123] may show an alternative advantage: the
epitope density is fixed regardless the chain length, whereby
the best affinity can be always achieved for 100% occupancy as
long as epitope spacing is optimized.[124] Additionally, chelating
effects are easier to generate. As last alternative, the attachment
mode can be also considered for tuning the epitope presenta-
tion. Usually, sugars are O-linked through the anomeric carbon,
but C-glycosides have been demonstrated to be beneficial in
terms of affinity and multivalence, likely due to their higher
conformational dynamics.[125] Also, the linkage might be created
at position 6, as long as the coordination to the primary site
remains unperturbed.[126]
Ligand density can also change the accessibility to alter-
native binding poses for certain epitopes, sometimes provoking
steric hindrance problems which lead these ligands to exhibit
smoother affinity enhancements.[112,127] As example, Man-coated
gold nanoparticles display higher affinities for DC-SIGN when
they are functionalized with the Manα1-2Man disaccharide
rather than with Manα1-2Manα1-2Man or Man5.
[121] To reach
very high inhibitory potencies, the exposed surface should be
increased such that the available residues grow while maintain-
ing an optimal epitope density and accessibility. In this regard,
the combination of rigid elements and flexible spacers must be
thoroughly controlled.[128,129] In sugar-functionalized fullerenes,
flexible long spacers have been efficiently used to exponentially
increase the amount of exposed residues up to 120 Man,
enhancing inhibitory potencies below the nanomolar range.[130]
The quest for better inhibitors can be further focused on
reducing the flexibility of the sugar-coated structure, thereby
minimizing the entropic penalty. This has been recently noticed
for hexavalent scaffolds with either rigid rod-shape cores or
completely flexible chains (Figure 5, top).[128] Alternatively, rigid
sugar glycoclusters, as those based on calyx[4]arenes, may help
to concentrate the sugar epitopes at specific positions,
enhancing sugar rebinding phenomena and likely contributing
to receptor clustering.[131]
Neoglycoproteins are another source of large sugar-coated
structures, also utilized as lectin receptors.[89,132] As notable
breakthrough, the capsid protein of the Qβ bacteriophage has
been applied for building glyconanoparticles coated with more
than 1000 Man residues.[133] Each protein possesses a modified
amino acid which harbors a nonavalent dendron. At the same
time, these capsid components self-assemble into 180 unit
spherical particles.[134] The resulting structures can strongly
inhibit EBOV infection with IC50 values within the low nano-
molar range.[133]
The aforementioned rigid hexavalent structures carrying the
dimannoside mimetic can be relatively quickly internalized at
physiological temperature, driving DC differentiation and matu-
ration through production of cytokines (IL-6, TNFα).[135] In
contrast, recently reported star-shaped glycopolymers cannot
activate DCs via DC-SIGN unless they are co-stimulated with LPS
and IFN-γ.[136] In other cases, ligand presentation directly affects
antigen internalization.[137] To exemplify, dimannoside-contain-
ing clusters have been noticed to be preferentially shuttled
inside DCs than the trimannoside-based analogues.[138] Similarly,
DC-SIGN promotes uptake of fucosylated oligolysine scaffolds,
but not of the mannosylated ones.[139] In all these cases, it is
always important to consider the different responses that might
be driven by similar CLRs, like MR or langerin.[137,139,140]
Frequently, a common strategy to trigger an efficient DC-
mediated immune response consists of combining sugar
epitopes for CLRs and other ligands to co-stimulate Toll-like
receptors, achieving for instance effective antitumor




3007ChemBioChem 2020, 21, 2999–3025 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Dienstag, 03.11.2020


























































also exploited for intracellular delivery of therapeutic agents,[142]
and for this purpose, sugar-coated liposomes are ideal plat-
forms. In general, micelles and liposomes are quick pathways to
afford enormous multivalent structures from suitable function-
alized lipids. For instance, the conjugation of Manα1-2Man
nonavalent dendrons to fully saturated aliphatic chains has
been successfully applied to inhibit HIV trans-infection of
DCs.[143] In the same line, liposomes coated with Lewis-type
Table 2. Examples of Man-coated multivalent scaffolds successfully used to inhibit DC-SIGN binding to potent Man-based biological epitopes, as viral
glycoproteins or viral strains. Gray zig-zag lines represent synthetic linkers.










22 Manα(1-2)Man[a] Raji-DC-SIGN+ cells infected with HIV-1 (JR-Renilla R5) 2.04 [118]
Neoglycoproteins
36 Manα(1-2)Man DC-SIGN targeted by Eu-DTPA-labeled Man51-BSA 0.8 [132]
Linear glycopeptides
17 Man[a] DC-SIGN targeted by gp120 (HIV) 48 [124]
Glycolipid dendrons and sugar-coated micelles
9 Man (per dendron)[b] MAGI-CCR5 infected with HIV-1 (NL4-3 R5) 500 [143]
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antigens stimulate DC activity and cross-talk with T cells.[144]
Recently, these platforms have been efficiently used for the
delivery of antigenic mRNA in mice, which can induce specific
tumor repression.[145] It is worth mentioning that cyclodextrins
functionalized with sugar chains can work as carriers as well.
However, in such cases, the loading of lipophilic compounds
may be hampered by the external polar sugar layer.[146]
Overall, the design of potent DC modulators is still
challenging. Although multivalence is in general the most
employed strategy to overcome the poor intrinsic affinities of
C-type lectins, computational and screening studies have
gradually directed the attention to other novel DC-SIGN
ligands.[147,148] Indeed, previous works have already found non-
sugar fragments with remarkably low affinities compared to
monosaccharides (μM; Figure 6A and B),[149] and some of them
are able to efficiently trigger cell signaling when conjugated to
a protein scaffold.[150] Fragment screening analyses have identi-
fied other potentially druggable sites in the CRD
architecture,[151] which could be exploited for the design of
more potent DC-SIGN modulators (Figure 6C).
3. Langerin
Langerin (CD207) is another type II C-type lectin receptor
involved in the attachment and uptake of invading pathogens
during the first stages of the immune response.[152,153] As
defining feature, the expression of this receptor is almost
exclusively limited to Langerhans cells (LCs), a subset of
immature dendritic cells originated from myeloid precursors
that finish their migration at the epidermis and mucosal
epithelium.[154] Langerin is known to drive the formation of the
so-called Birbeck granules (BGs), particular organelles found on
LCs and constituted by several zippered membranes forming
rod-like structures, which probably take part in the endosomal
recycling pathways.[155] As other CLRs, this receptor has been
reported to act as anchoring and internalizing factor in many
infectious processes, involving bacteria,[156] fungi[157] and
viruses.[158] Remarkably, at low viral load, langerin is able to
promote the efficient internalization and degradation of HIV
particles, protecting LCs from infection and avoiding viral
transmission to lymphocytes.[159] However, there is still some
controversy regarding the exact roles of langerin in HIV
infectivity.[160] Subsequent works have evidenced the efficient
infection of LCs orchestrated by langerin and the further
transmission of the viral particles to T cells.[161] Certainly, HIV
susceptibility may depend on other complex factors besides the
viral load, including the cell models used in the assays and the
infection phases.[162] In this regard, good LC models are
generally difficult to reproduce and the published data maintain
this discussion opened yet. Additionally, murine models have
shown that LCs preserve their phenotype and normal functions
in the complete absence of langerin, just lacking the ability to
generate the BGs[163] and feeding even more the mystery about
the exact physiological role of this lectin. Nowadays, the scope
of study and the importance of this receptor are progressively
becoming broader. Recently, langerin has been proposed, along
with DC-SIGN, as a relevant receptor in oral cancer episodes
through the recognition of highly-fucosylated glycans on cell
surfaces.[164] Also, similar to DC-SIGN and L-SIGN,[165] langerin can
act as an entry receptor for influenza A virus (IAV), even in the
absence of surface sialylation,[166] thereby confirming it as the
major mediator in IAV infections occurring on LCs. This “duality”
turns this protein into a challenging target for the development
of therapeutics, as it might promote infectivity in some cases
while exerting a protective role in some others, triggering the
formation of BGs. Hence, a better understanding of this
receptor is still pursued to date, especially regarding the
existing disparities with DC-SIGN in HIV transmission. In this
aspect, the development of highly specific drugs discriminating
DC-SIGN from langerin is highly desirable, as they should not
affect the natural defense created by langerin.
Early studies with mouse langerin already showed that this
lectin can recognize mannose-capped glycans.[167] Its structure is
essentially composed of a cytoplasmic domain, a transmem-
brane segment, and an extracellular portion including the neck
repeats and the Ca2+-dependent CRD.[168] Accordingly, its CRD
presents the typical structural elements of a C-type lectin-like
domain, including the EPN motif commonly associated with
Man/Fuc selectivity.[7b,11,169] Its sugar preferences are fairly similar
to those of DC-SIGN:[63] Langerin recognizes Man, Fuc, Glc and
GlcNAc monosaccharides with low millimolar affinities, as well
as high-Man glycans (Figure 7). Conversely, it is unable to
interact with complex multi-antennary glycans, either capped
with sialic acid or not.[170] In addition, its corresponding mouse
homologue was surprisingly discovered to interact with dextran
sulphate and with epitopes containing terminal 6S-Gal as
well.[171] This exquisite selectivity is likewise observed in the
human variant and further complemented with some differ-
ences regarding the recognition of Lewis-type antigens. In
contrast to DC-SIGN, langerin cannot bind to LeX and LeA
antigens, while recognition of LeY and LeB, as well as the blood
group antigens A and B, is maintained (Figure 7).[90,172] These
findings point out a limited ability for the exclusive recognition
of terminal α1-2-linked Fuc residues, suggesting a possible
protective role of the natural LeX-containing antigens as
Figure 6. Some non-sugar inhibitors described for DC-SIGN and their
affinities. A) and B) Active compounds found by fluorescent assays. C) Active
fragment detected and validated by NMR. Note, it still binds to DC-SIGN in
the absence of Ca2+, thus suggesting that the interaction is not established
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selective binders for DC-SIGN, given that these epitopes are
abundant in human milk.[173]
The fact that langerin can mediate recognition processes
with sulfated sugars immediately raised the question about its
interaction with glycosaminoglycans (GAGs) and its potential
biological role in such a context. Langerin has been reported to
recognize sulfated Gal and GlcNAc residues, both present in
keratan sulfate (KS) and heparin-related GAGs, respectively
(Figure 9). Interestingly, the studies with sulfated LacNAc
disaccharides have evidenced the existence of certain structural
requirements underlying the stability of these interactions.[174,175]
Thus, binding takes place when the 6S group is placed at the
nonreducing Gal, whereas the presence of sulfate groups at the
inner GlcNAc moiety seems to be irrelevant. Moreover, the
interaction is abrogated after terminal sialylation (sulfated sialyl-
LacNAc) or when the sulfate group is attached at position 3.[176]
It is worth noting that 6S-GlcNAc can be actually recognized as
free monosaccharide. All these findings underline the crucial
role of the sulfate group at position 6 in the Gal scaffold,
making possible the recognition of this sugar by an EPN lectin.
From the protein perspective, two lysine residues (K299 and
K313) exclusively present at the secondary site of langerin, and
not at other C-type lectins, are responsible for the stabilization
of the negatively charged SO4
  group through a double salt
Figure 7. Qualitative comparison between the sugar preferences of DC-SIGN and langerin. The central area displays those epitopes similarly recognized by
both receptors. To clarify, Gal has not been included as free sugar, as the dissociation constants are rather high in both cases. Only langerin recognizes
sulfated moieties, including Gal and Glc, although it preferentially targets outer Man residues in complex glycans. Also, DC-SIGN interacts with a wider range
of fucosylated structures and more easily accommodates Man residues from highly branched scaffolds.
Figure 8. Crystallographic models obtained for langerin interacting with different mono- and oligosaccharides. Sugars are colored as follows: Man: green, Fuc:
magenta, Gal: yellow, Glc: blue. Residues A289, K299, K313, F315, and V351 are shown as sticks in all structures, other relevant amino acids are labeled in
particular cases. A) Man2 (PDB ID: 3P5F). B) Blood group B trisaccharide (PDB ID: 3P5G). C) 6S-LacNAc (PDB ID: 3P5I). D) GlcNS6S (PDB ID: 5G6U). E) α-OMe-
GlcNAc (PDB ID: 4N32); on the right is a mimetic scaffold based on the binding pose of GlcNAc, bearing an aromatic moiety to establish aliphatic contacts
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bridge (Figure 8C).[174,177] Despite the restricted binding to
terminal sulfated sugars, linear KS chains[178] have been found to
exhibit enhanced affinities (ca. 100-fold lower KD values), which
additionally correlate with their SO4
  content, suggesting the
existence of avidity effects typical from systems with several
available epitopes. Otherwise, recently reported synthetic
polymers capped with terminal 6S-LacNAc units have been
shown to display very potent affinities (nM) and are able to
exert anti-inflammatory activities in mouse models with chronic
obstructive pulmonary disease (COPD).[175,179] These results
certainly represent a new frontier in the treatment of COPD in
cigarette smokers, as Langerhans cells have been reported to
accumulate in broncoalveolar tissues of COPD patients.[180]
As for other C-type lectins, the langerin-mediated recogni-
tion of Man-containing oligosaccharides has been exhaustively
investigated from the structural perspective, especially using X-
ray crystallography. Interestingly, in most structures (Man2,
Man4, Man5)
[177,181] the Ca2+-coordinated Man residue has been
found to display the opposite ring orientation to that observed
for the analogous DC-SIGN structures (Man2, Man4, Man6).
[79,85] In
such an orientation, the axial OH2 targets the polar side chain
of the nearby K299 and the remaining glycan structure,
although not modeled, should point away from the lectin
surface (Figure 8A). These models intriguingly suggest that
langerin probably would not bind to the inner Man residues of
the Man9GlcNAc2 glycan, since this orientation would preclude
the accommodation of the outer Man moiety at the secondary
site, due to the protruding lysine side chains. Even so, the
Manα1-2Man disaccharide displays the two alternative presen-
tations in the crystal with similar occurrence (ca. 50%). In this
case, although the alternative orientation enables binding
through the reducing Man, the accommodation of the
extended glycan structure would be expectedly more limited
than that reported for DC-SIGN. In any case, recent NMR data[182]
using the same disaccharide also support that langerin
preferentially binds to the nonreducing Man residues, addition-
ally suggesting that the neighboring moiety provides stabiliza-
tion through packing against the Ala289 side chain.
Regarding other sugars, several X-ray diffraction structures
have provided insights into binding of Glc-containing scaffolds
to langerin. The complexes with maltose (Glcα1-4Glc)[181] and
laminaritriose (Glcβ1-3Glcβ1-3Glc)[177] highlight that the primary
epitope is always the nonreducing Glc, which coordinates the
calcium ion through hydroxy groups at C3 and C4. Remarkably,
the Glc ring adopts the same orientation than the Man
analogue described above, but creating a stabilizing polar
contact with K299 through OH6 instead of OH2. The scenario is
identical for α-OMe-GlcNAc, with the additional contribution of
the N-acetyl group, which establishes water-mediated polar
contacts with K299 and N297 and also van der Waals contacts
between the methyl group and the aliphatic side chain of P310
(Figure 8E).[183] Recently, langerin has been crystallized bound to
GlcNS6S, and the model displays the sugar in the opposite
orientation (Figure 8D).[110] This alternative binding mode suit-
ably justifies the increased affinity observed for sulfated GlcNAc,
as the sulfate group at position 6 is crucial to target K313,
creating a stable electrostatic contact. In this case, K299 is
placed further away and does not seem to be as important as
reported for 6S-Gal. Indeed, mutation studies have confirmed
this hypothesis.[110] Finally, only one X-ray crystallographic
structure of langerin has been described in the presence of the
Fuc-containing B antigen (Figure 8B).[177] In the crystal, the Fuc
ring coordinates the metal ion through positions C2 and C3, as
opposed to the OH3-OH4-mediated calcium-binding described
for selectins[103] and for DC-SIGN.[83,85] Besides the primary
epitope, the nonreducing Gal moiety also contributes to the
stabilization of the complex, providing polar contacts with P283
and N287.
Given the importance of the amino acids surrounding the
calcium binding site for the fine selectivity of langerin, several
investigations have thoroughly analyzed the impact of single
nucleotide polymorphisms (SNPs) in the overall functionality of
this lectin. Some mutations slightly affect to the CRD stability
without decreasing the sugar affinities, as A278 V. In contrast,
the N288D and A300P variants give rise to a tenfold lower
affinity for Man.[184] Also, the W264R mutation is a rare variation
that completely abrogates the recognition of any sugar and
also precludes the formation of BGs.[185] By thermal shift assays,
this mutation has been recently proven to disrupt the entire
CRD folding.[186] The already mentioned N288D variant has
particularly attracted more attention given that it is more
recurrent (ca. 11%) and often appears associated to another
mutation: K313I. This latter structural change has a dual
consequence: the ability to stabilize sulfated glycans is
completely lost, while the affinity for GlcNAc seems to
increase.[183] The second effect is justified by a higher hydro-
phobic stabilization of the N-acetyl group jointly contributed by
P310 and I313. The recognition of high-Man glycans and histo
blood group antigens is in principle maintained in the single
mutant, whereas the affinity drop observed in the double
mutant (N288D, F313I) could be driven by the disruption of the
normal H-bond network around the calcium ion.[183,184] The
Figure 9. Schematic structure of the most relevant glycosaminoglycans
(GAGs). All GAGs consist of a repeated disaccharide unit constituted by an
acetylated sugar and an uronic acid. Chondroitin sulfate (CS) and dermatan
sulfate (DS) share a GalNAc unit that can be sulfated at O4 and/or O6.
Keratan sulfate (KS) displays a sulfated Gal instead of an uronic unit. Heparins
and heparan sulfate (HS) are fairly heterogeneous, they can contain variable
amounts of IdoA and GlcA. Often, heparins are highly sulfated (up to three
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study of the murine homologue of langerin has also helped to
clarify how the structural differences on key amino acids lead to
noticeable changes in specificities. At the monosaccharide level,
the sugar preferences of murine langerin are fairly conserved.
Surprisingly, it recognizes 6S-Gal in spite of lacking both K313
and K299 (N316 and R302, respectively),[182] which has been
attributed to the presence of a shallower and wider secondary
site able to accommodate bulky groups or other substituents
from larger structures, similar to DC-SIGN. Moreover, X-ray data
suggest that the oligomeric structure is more flexible for the
murine homologue, enabling higher avidity effects in the
presence of multivalent scaffolds. In fact, glycan arrays have
evidenced that murine langerin can bind to a broader range of
microbial complex oligosaccharides, although human langerin
still exhibits an exclusive ability to recognize some epitopes
from Yersinia pestis, Shigella flexneri or Escherichia coli.[182] From
a general perspective, all these findings reflect fairly well the
complex interplay between the primary interactions, the
secondary epitopes, and the multivalent phenomena, which in
turn shape the fine specificity of a given receptor. Finally, with
regard to multivalent interactions, the F241L mutation has been
described to cause an abnormal formation of the BG structures,
although the sugar recognition ability is kept.[186] Certainly, the
interaction with sugars does not change for the CRD, but there
is a noticeable drop in the expected affinity of the oligomeric
extracellular domain. A closer inspection of the X-ray models
has revealed the loss of certain contacts between secondary
structure elements (α1 and β0) at the N-terminal regions of the
CRD, which would eventually contribute to disrupt the correct
3D arrangement of the whole oligomer.
In solution, the ECD of langerin exists associated into trimers
which remain stable even at acidic pH values (ca. 4.0).[170] AUC
and SAXS measurements, combined with modeling tools, have
revealed that the neck repeats constitute a highly structured
coiled-coil only interrupted at two regions (around residues 100
and 150).[186,187] These observations contrast with the more
flexible arrangement found, for instance, for DC-SIGN or L-SIGN
tetramers,[75a,76] where each neck repeat forms an independent
α-helix within a single protomer. Additionally, a truncated
version of the trimer could be crystallized, unveiling key neck-
CRD interactions within the same protomer and between
neighboring protomers.[176] Taken together, all these data
underline that both CRD and neck regions may synergistically
contribute to define the 3D shape of the oligomer, eventually
resulting in trimers that adopt a fairly rigid conformation. Such
an arrangement has been also noticed for other receptors from
the collectin family (Group III)[188,189] and could explain the
weaker avidity effects generally seen for the langerin ECD in the
presence of high-Man glycans.[182] Another factor to consider is
the influence of pH: C-type lectins often act as endocytic
receptors, and the cargo release takes place in the early
endosome under acidic conditions. These conditions usually
lead to a decreased Ca2+ affinity, which in turn hampers the
normal attachment of the sugar, allowing its release.[190,191] In
the case of langerin, molecular dynamics simulations supported
by experimental NMR data have evidenced that dynamics of
the short and long loop regions surrounding the Ca2+ site are
connected and regulated by a complex allosteric network
involving multiple amino acids.[192] A thorough analysis of the
CRD dynamics using different mutants have allowed checking
the strong robustness of such a network, which is meant to
downregulate the Ca2+ affinity in acidic environments. In
particular, H294 has been found as a potential pH sensor
helping in this process, although other relevant residues are
supposed to participate as well.
As commented on above, the interaction of langerin with
GAGs was unexpected at first, although it was structurally well
justified taking into account secondary interactions provided at
neighboring sites. However, along the last decade, the recog-
nition of long heparin chains (>6 kDa) has been surprisingly
found to happen in a Ca2+-independent fashion.[193] In fact, it
seems that this type of interaction is barely supported by the
sole CRD, whereas the trimeric ECD can strongly bind to these
heparins either with or without Ca2+. Heparins are anionic
polysaccharides frequently sulfated, with a high structural
variability, and are involved in many relevant biological
functions.[194] Their ability to target langerin even in the absence
of calcium strongly brought forward the idea that these GAGs
might be involved in langerin-mediated functions at the early
endosome, such as BG formation or regulation of the cargo
release. However, to date there is not yet a clear consensus
about the key structural aspects underlying the recognition of
large GAGs. From a general perspective, langerin preferentially
binds to heparin and heparan sulfate (HS) over chondroitin (CS)
and dermatan sulfate (DS).[193,195] Such preferences seem to be
governed by both the amount of sulfate groups and their
specific distribution pattern (Figure 9). Thus, GlcNAc moieties
play the most important role, as desulfation at either O6 or N2
negatively affects to the interaction, whereas sulfation at the
uronate moiety (IdoA) does not seem to be as relevant.[195]
Fittingly, significant binding has also been reported for CS-C,
the CS subtype with major sulfate content at positions C6 and
N2. DS has been observed to maintain a weaker but still
noticeable level of binding as well, in spite of its low sulfation
rate at the mentioned positions.[193] This latter finding has
suggested a possible role of the IdoA moiety in the stabilization
of the complex, although this hypothesis remains partially
unclear due to the lack of structural data.
Coming back to heparins, an open debate still exists on
how or where long heparins do exactly bind to Langerin and
whether Ca2+ is really needed for such a binding. The length of
the heparin chain clearly influences both the mode of binding
and the affinities. Around six sugar units, the affinities start to
subtly increase faster, while the improvement becomes signifi-
cantly sharper above 16 sugar units.[195] It could be hypothe-
sized that the second increase is driven by avidity effects (ECD),
whereas the first one better correlates with the parallel
observation that Ca2+-independent binding already appears for
medium chain lengths. NMR data have evidenced that heparin
trisaccharides are recognized at the calcium site, and that the
interaction is exclusively mediated by the nonreducing GlcNS
regardless the sulfation pattern, as long as position N2 remains
sulfated.[196] In addition, STD and trNOESY experiments have
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conformations of the IdoA pyranose substantially change upon
binding, compared to those described in the free state.[197]
Conversely, the STD-NMR values collected for heparin hexasac-
charides display a more homogeneous saturation profile.[196]
From the protein perspective, these hexasaccharides curiously
tend to mostly affect the allosteric network previously
described in the modulation of the Ca2+ affinity.[192,198] Taken
together, these results point out the existence of a completely
unique interaction between heparins and langerin. A docking
model was first proposed using a ten-residue heparin chain, in
which the entire oligosaccharide establishes electrostatically-
driven interactions with the positively charged interface
between two CRDs of the trimer.[193] In principle, this model
would reasonably fulfill the subsequently published data,
including the STD profiles,[196] the CSPs found by HSQC-based
titrations[198] and the essentially electrostatic nature of the
interaction (disrupted with NaCl).[195,199] However, there are still
some findings which require further justification. For instance,
the proposed docking models suggest a more important role
for sulfate groups at N2 than at C6 (salt bridges),[193] but recent
reports have highlighted that the Ca2+-independent binding
can be perfectly sustained without N2 sulfation. Also, some
degree of Ca2+ dependence co-exists during the binding event,
although it changes with the sulfation pattern as well.[198] So far,
the interplay between the classic Ca2+-mediated and the
alternative sugar binding for heparin-langerin complexes is not
fully understood.
Finally, it is worth mentioning the reported advances for
developing specific langerin-binding sugar mimetics. Certainly,
langerin features a more reduced and particular specificity than
related lectins such as DC-SIGN or Dectin.[200] It cannot recognize
LeA and LeX antigens and presents a limited ability to target
inner Man residues in highly branched scaffolds, in part due to
the two protruding charged lysine side chains near the calcium
site. These two side chains have been actually exploited for the
design of bulky and positive substituents which can preclude
binding to langerin while still targeting DC-SIGN, thereby
improving the selectivity for the latter.[110,111] Even so, the
development of novel specific and potent sugar mimetics
remains challenging given that the intrinsic CRD architecture
displays very exposed and polar surfaces that are rather
undruggable, as already suggested by computational
methods.[147] Of course, screening techniques are suitable to
reduce the time costs in this quest, but require from the
appropriated setup to undertake a reliable and fast enough
evaluation of large libraries. Recently, a promising screening
method has been developed and simultaneously tested with
DC-SIGN and langerin.[148] The method enables a better
evaluation of the binding potencies under physiological
conditions, directly on the CLR-containing cells (Figure 10A).
Detection of hits is achieved by direct competition between a
reference fluorescent ligand (FITC-dextran) and the tested
fragments. Expectedly, a low percentage of hits were identified
for both lectins (5.6% for langerin and 12.3% for DC-SIGN). In
both cases, some hits were subsequently validated by orthogo-
nal assays, employing SAR analyses and the fast NMR-based 19F-
T2 and HSQC setups previously designed and tested for the
studied lectins.[151,201]
As recent breakthrough, the GlcNS monosaccharide has
been successfully used for the development of an improved
scaffold which can be covalently linked to a multivalent system.
Although the affinity barely varies, there is a 63-fold increase in
the selectivity respect to DC-SIGN. The resulting structure bears
an aromatic system on the sulfonamide group which presum-
ably provides stabilizing hydrophobic contacts with Phe315
(Figure 8E).[202] In this regard, NMR data supports that the
sulfonamide substituent is located at the region surrounding
Lys299, where the C2 substituent additionally establishes polar
interactions with Asn307 as well as the cited aliphatic contact.
In contrast, Lys313 and Pro310 do not seem to play any
Figure 10. A) Summary of the cell-based fragment screening assay (Cell-Fy) developed to directly screen compounds against lectin-expressing cells.[148] As
depicted, the detected hits are further validated by NMR techniques. B) Langerin binding to LeB and LeY using different ligand formulations.[137] Langerin ECD-
Fc can recognize both antigens coated on a plate and linked to the tumor-associated peptide MART-1. Moreover, the latter are successfully internalized by
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substantial role in the recognition. Subsequent linking of these
mimetics to lipid chains enabled the development of sugar-
coated liposomes, which are successfully internalized by
Langerhans cells in epidermal cell suspensions from skin
biopsies.[202] To note, these liposomes also exhibit low cytotox-
icity levels and the binding avidity can be controlled through
the surface density of the single mimetic. Interestingly, they are
internalized in any case, in contrast to other LeY-coated
liposomes tested before.[137] These findings highlight the
importance of both the liposome formulation and the chosen
epitope, as the nature of the latter one may exert different
effects on multivalent lectin targeting depending on its surface
density (Figure 10B). Eventually, langerin-specific liposomes can
serve as straightforward methods for transcutaneous vaccina-
tion via LC targeting,[203,141b] with some advantages with respect
to mABs-based vaccines, especially regarding the final cargo
release.[204,80b]
4. Macrophage Galactose Lectin (MGL)
The human macrophage galactose lectin (also dubbed CD301
or CLEC10A) is a calcium-dependent transmembrane receptor
included within the group II of C-type lectins.[7a] In contrast to
DC-SIGN and langerin, its structure displays the characteristic
QPD motif at the long loop region, typically associated to
galactose (Gal/GalNAc) specificity.[11,169] In the biological context,
this receptor has progressively gained much attention over the
last two decades due to its involvement in tumor development
and progression.[6,205,207] In a physiological environment, MGL is
known to participate in activateion of dendritic cells for
undertaking subsequent T cell downregulation or even induc-
ing apoptosis of effector T cells.[208] The upregulation of this
receptor specially takes place on tolerogenic APCs (DCs and
macrophages)[209] and, in principle, it is thought to have a
protective role in persistent inflammations and autoimmune
diseases, preventing excessive tissue damaging and alterna-
tively allowing their remodeling.[208,210] In the same line, tumor
cells may escape from immune clearance through MGL
targeting via the specific recognition of tumor-associated
glycan motifs, which are not present in healthy tissues.[211] For
this reason, MGL has become a potential target for the
development of biomarkers, therapeutics and vaccines against
cancer.
The sugar preferences of this receptor have been largely
studied to better understand its biological roles in the establish-
ment of self-tolerance, especially in tumor tissues. Over the last
decades, several tumor-associated carbohydrate antigens (TA-
CAs) have been postulated as MGL counterparts and their
corresponding recognition processes have been investigated in
detail. One of the most important TACAs is the Tn-antigen
(GalNAc-α-1-O-Ser/Thr), whose structure was already unveiled
in the seventies.[212] Its presenceinvolvement in human tumors
has been largely described[213] and it characteristically appears
as distinctive motif in aberrant glycoforms of MUC1 proteins
(Figure 11).[214,215] Similarly, MGL is able to recognize other
related antigens present in tumor tissues including the
Neu5Ac  Tn antigen and the Neu5Gc  Tn antigen.[216,217]
MGL was first purified from transfectants and the first assays
suggested that it could recognize both Gal and GalNAc
residues.[218] Later, it was discovered to oligomerize in solution,
forming homotrimers.[219] The access to pure recombinant forms
of this protein has allowed a better and detailed inspection of
its ligand specificity, using the glycan array developed by the
Consortium for Functional Glycomics.[220] Importantly, the high
specificity of this lectin for α-GalNAc and the Tn antigen
Figure 11. Schematic overview of the MUC-1 structure.[243] On the top, the 20-amino acid sequence that constitute one tandem repeat. On the bottom, the
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(GalNAc-α-1-O-Ser/Thr) was confirmed, whereas α/β-Gal is
barely recognized. MGL is also able to interact with β-GalNAc,
suggesting that both configurations can be in principle
accommodated at the recognition site, as further seen in larger
glycans. In contrast, no binding has been reported for other
mono- or oligosaccharides devoid of GalNAc moieties, as
LacNAc, Lewis X or the glycosphingolipids GM3 and GD3. These
studies have also evidenced the MGL fine selectivity towards
GalNAc-containing entities, depending on the geometry and/or
configuration of the surrounding sugars. As terminal motif,
GalNAc enables MGL targeting mediated by LDN and LDNF
epitopes, commonly found on Schistosoma mansoni SEAs,[221]
and the glycosphingolipids GM2 and GD2. Conversely, the
attachment of other sugars in the GalNAc scaffold seems to be
limited to position 6 (O-glycan core 6, 6-sialyl-Tn, 6-sulfo-Tn),
while binding is totally abrogated after substitution at position
3 (cores 1–4, 3-sialyl-Tn).
The exclusive specificity of MGL is clearly different from that
of the related ASGPR receptor, found on the sinusoidal surface
of hepatocytes.[222] This latter CLR has been extensively studied
since its discovery in the early sixties,[223] and is known to bind
to either terminal Gal or GalNAc residues in highly branched
structures.[224,225] In contrast, MGL has been less investigated
even in comparison with other related C-type lectins as DC-
SIGN[26,27] or MMR,[226] whose biological relevance was guessed
at the same moment. The lack of crystallographic models for
this lectin may explain in part this slower progression from the
molecular perspective, as these models often speed up the
interpretation of data from other sources and help to hypothe-
size about the recognition of other unknown ligands. In such a
scenario, NMR has emerged as the primordial tool to unveil the
structural details underlying the recognition of GalNAc-contain-
ing glycopeptides by MGL. STD experiments have permitted to
closely evaluate the ligand epitope of the primary monosac-
charides, α-Gal and α-GalNAc, using the recombinant MGL-ECD
domain.[227] As reported for other galactose-specific lectins,[228]
binding takes place through coordination of hydroxy groups at
C3 and C4 to the calcium ion. However, two orientations are
possible for the sugar ring considering the hydroxy positioning.
As no X-ray models of MGL are available, the evaluation of
these poses by docking is still performed by using a homology
structure based on an ASGPR crystal.[229] For GalNAc, two
possible orientations were postulated to explain the experimen-
tal STD-NMR data, whereas experiments with Gal better
adjusted to the existence of an unique binding mode.
Interestingly, STD-NMR data from Tn-derived mucin-like pep-
tides support the involvement of the peptide sequence closer
to the GalNAc attachment in secondary contacts with the
protein surface. In any case, the non-glycosylated peptides do
not provide any STD signal, assessing the role of the sugar as
primary epitope for MGL.
In view of these results, new questions were opened
concerning other effects, such as the nature and influence of
the nearby sugars or the proper peptide chain. MD calculations
have validated the importance of the acetyl group of GalNAc in
the binding, thereby explaining the 75-fold better affinity for
GalNAc (12 μM) than for Gal (ca. 900 μM).[227] However, GalNAc-
bearing peptides display similar dissociation constants in spite
of the additional stabilizing contacts arising from the peptide
chain, as deduced by STD-NMR (Figure 12G). Although merely
speculative, these discrepancies may arise from enthalpy-
entropy compensation phenomena.[230] In parallel, the effects of
additional sugar residues in GalNAc-mediated binding to MGL
have been also studied for other relevant sugar epitopes. STD-
NMR analyses performed for Tn and sialyl-Tn antigens have
evidenced saturation profiles and affinities rather similar to the
α-OMe-GalNAc epitope, in the low-micromolar range.[217] Both
antigens display important STD NMR effects at H2, H3, H4 and
the acetyl group, although this latter yields higher STD
percentages for the sialylated antigen. It is worth noting that
the sialic moiety provides additional STDs at H3ax and its acetyl
group (Figure 12B). However, SPR measurements have shown a
slightly reduced affinity for sialyl-Tn, presumably arising from a
slower kon rate. Recently, the interaction of recombinant MGL-
ECD with other four GalNAc-containing epitopes has been
thoroughly investigated by NMR, assisted by MD simulations
using the homology model.[232] Three of these oligosaccharides
(BgA, Forsmann and GM2) have been already reported as
tumor-associated antigens,[233] and hence might act as MGL
ligands contributing to tumor surveillance. To highlight, 15N
HSQC-based titrations on a 15N-labeled MGL monomer revealed
interesting findings. In all cases, including the four studied
ligands and the simplest epitope (α-OMe-GalNAc), the binding
takes place in a slow-exchange regime in the NMR chemical
shift timescale, suggesting substantially long residence times
for all these ligands at the binding site (small koff). Moreover,
upon ligand addition, some protein crosspeaks appear or get
sharper, especially those from the loop regions close to the
binding site. These observations actually prove the conforma-
tional stability gain that the flexible regions of MGL experience
as a result of glycan binding, similar to that observed for other
lectins.[83] For the blood group A trisaccharide, no significant
differences were found with respect to α-OMe-GalNAc and
indeed, only the terminal GalNAc residue provided relevant STD
NMR effects (Figure 12A and C). The scenario is similar for the
Forsmann antigen, for which the STD-NMR results underline
again the lack of close lectin contacts with the central and
reducing saccharide moieties (Figure 12D). In deep contrast,
both GM2 and asialo-GM2 ligands display better affinity
constants and strong STD NMR effects, several of them located
even at the reducing-end sugars (Figure 12E and F). Fittingly,
some lectin crosspeaks from the binding region were actually
affected in a different fashion in the 15N HSQC spectra depend-
ing on the ligand added (Lys264, His286). Although the results
from MD should be considered as merely approximated, given
the homology-model-based starting geometry employed,
His286 provides a stable H-bond with the N-acetyl group of the
attached GalNAc and a CH-π contact with the reducing end as
well, pointing out the role that this residue may play in the
stabilization of certain extended epitopes. Indeed, a recent
report has evidenced the loss of binding provoked by a
mutation of such a residue using the MGLshort splice variant
(H259 instead of H286).[234] The mutant H259T is unable to
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sialyl-Tn, whereas binding to α-OMe-GalNAc or the O-glycan
core 6 is preserved.
The quest for biological epitopes that could be targeted by
MGL has recently led to evaluate the ability of this lectin to
recognize the novel GalNAc-Tyr antigen. Since 2011, several
proteins have been found to present this particular motif,
consisting of a GalNAc monosaccharide attached to the
phenolic OH group of a tyrosine residue.[235] The biological
significance of this glycosylation remains still unclear, as it is
rather difficult to produce and detect. In any case, analogously
to the Tn antigen, MGL has been evidenced to recognize it as
well.[236] Using short glycopeptides loaded on a BSA scaffold, the
affinities of the Tn antigen and the GalNAc-Tyr antigen have
been checked to be very similar, especially when the ligand
densities on the BSA surface are high. In both cases, the best
affinity values have been found around 30–40 nM. Apparent Kd
values show no relevant preference for α- or β-GalNAc-Tyr, and
both configurations are similarly bound especially at higher BSA
glycan coating.[236] To note, the configuration of the sugar
linkage in natural GalNAc-Tyr antigens has not been yet
clarified, as it has only experimentally assessed in one case so
far (“α” in the Aβ1-15 peptide).[237] Finally, in vitro cultures using
the homologue receptor mMGL2, which has a ligand selectivity
very similar to hMGL,[238] suggest that uptake of GalNAc-Tyr-
containing entities by human DCs could be likewise driven by
MGL.[236] STD-NMR experiments using the most potent glyco-
peptide confirmed the possible participation of the nearby
amino acid side chains in the extended epitope, as reported for
the Tn antigen.[227] In the same line, other recent works have
focused on identifying those specific glycoproteins that might
act as MGL counterparts in cell-cell cross-talk. In particular, pull-
down experiments with three different colorectal cancer (CRC)
cell lines have led to identify up to 85 membrane glycoproteins
that are specifically recognized by MGL-Fc.[239] Most of them
include cell surface signaling receptors and integrins. Addition-
ally, subsequent analyses of the glycan content by MS/MS have
revealed the presence of the LacDiNac (LDN) epitope in several
cases (ITGA3, PTK7) as well as the Tn antigen (DAG1). Strikingly,
Figure 12. Schematic representation of the STD profiles described for different MGL ligands.[217,227,232] To clarify, for each antigen only those STDs above 50% in
relative scale are depicted as red circles. In all cases, recombinant soluble MGL-ECD has been used for data recording (in B, it was additionally tagged with
myc and associated to anti-myc AB and streptavidin). A) α-OMe-GalNAc. B) sialyl-Tn antigen. C) Blood group A trisaccharide. D) Forsmann antigen. E) asialo-
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other glycoproteins were found to bind MGL in spite of carrying
glycan structures that were not expected to be MGL ligands
according to the reported data so far, for instance high-Man
scaffolds or sialyl-T antigens. Given the plasticity widely known
for these type of lectins,[82,240] it is likely that weak binding of
individual ligands might be largely enhanced by multivalent
effects (or high epitope densities), thus explaining the results
commented above. Conversely, the lack of binding for known
ligands often comes from unfavorable geometrical factors
imposed by the epitope environment. In this regard, recent
works have attempted to shed light into these questions, not
only studying the effect of the glycan density, but also how the
number and distribution of Tn and related epitopes in mucin
peptides modulate MGL binding.[241,242] The MUC1 N-terminal
peptide is constituted by repeats of 20 amino acids, being five
of them serine and threonine residues susceptible to O-
glycosylation (T3, S4, T8, S14 and T15; Figure 11).
[243] MGL has been
described to bind slightly better to the threonine-containing Tn
antigen, although the affinities for mono-GalNAc MUC1 repeats
are rather similar regardless the type of Tn epitope and its
location on the peptide sequence.[234,241] In contrast, interesting
differences have been observed for di- and tri-Tn MUC1
repeats.[241] In these cases, MGL can clearly recognize di-Tn
peptides at the same level, although the simultaneous presence
of Tn at the central Thr (T8) and the initial GVTS region (T3/S4)
seems to negatively affect the recognition event. To note, the
binding is maintained with two consecutive GalNAc motifs on
either the GVTS or the GSTA regions. This fact suggests that the
adjacent Tn antigen is suitably accommodated or at least does
not disturb the binding of the other Tn moieties. Overall, the
presence of more Tn antigens does not significantly contribute
to improve the affinities. Indeed, binding to MGL can be
sustained by MUC1 chains with multiple epitopes, but in these
cases, affinities tend to progressively worsen as the glycan
crowding increases. Parallel studies using synthetic linear
GalNAc-containing glycopolymers have proven that the dissoci-
ation constant subtly decreases within the 1.0–0.1 μM range
when exposing the MGL trimer to different GalNAc contents,
from 13 to 100 sugar units.[242] Interestingly, the same experi-
ments give rise to a noticeable enhancement in the affinities for
the related ASGPR lectin. From the receptor perspective, these
findings agree with the existence of “cluster effects”[115] that
could be readily engaged for the MGL ensemble, but not for
the ASGPR receptor. Broadly speaking, these results probably
reflect that the MGL trimer is flexible enough to independently
accommodate a GalNAc epitope in any of the CRDs taking
advantage of the high local epitope concentration. In contrast,
for the more rigid ASGPR ensemble, a suitable valence-depend-
ent targeting is needed for improving its weaker affinities.
Aside from tumor-related epitopes, other recent investiga-
tions have underlined the possible role that MGL could play in
bacterial infections as well. One example is found in Staph-
ylococcus aureus, one of the most prominent causes of health
care-associated pneumonia.[244] Usually, the exposed wall tei-
choic acid (WTA) chains in the cell wall of the pathogen consist
in a poly-ribitolphosphate backbone decorated with single α-
GlcNAc residues.[245] However, certain lineages can alternatively
decorate the negatively charged backbone with α-GalNAc units
(Figure 13). In particular, the GalNAc-WTA-expressing S. aureus
lineage ST395 has been reported to bind to MGL through these
exposed GalNAc residues.[246] The specificity of the recognition
process has been assessed by both observing the lack of
binding to GlcNAc-WTA-expressing strains and also, the loss of
binding after impairing the correct formation of the GalNAc-
decorated WTA structure (mutant devoid of GalNAc-trans-
ferases). In addition, in vitro studies with moDCs and this S.
aureus lineage have shown that MGL can induce the production
of certain pro-inflammatory cytokines (IL6, IL12p70), although
the host-bacteria interaction is not totally inhibited by blocking
MGL, suggesting the simultaneous participation of other
membrane receptors.[247] Similarly, a more detailed study has
permitted to depict the possible glycan epitope that MGL could
target in the truncated bacterial lipopolysaccharide exhibited
by Gram-negative bacteria. This shorter version of the LPS is
often named LOS (lipooligosaccharide), and constituted by two
cores, one consisting of heptoses (Kdo, hepMan) and the outer
one containing hexoses (Glc, Man, Gal; Figure 14).[248] In
particular, STD-NMR experiments have evidenced the ability of
MGL to target those LOS from E. coli R1 strains, which contain
the terminal disaccharide Galα1-2Gal.[249] As suggested by the
observed STD signals, the entire outer core (five residues) is
involved in close contacts with the lectin surface, especially the
cited disaccharide portion. The primary epitope (nonreducing
Gal) is fairly similar to that of the GalNAc-containing glyco-
sphingolipid scaffolds GM2 and asialo-GM2, suggesting that
calcium coordination probably occurs in the same way.[232] The
docking structures with the homology-model geometry support
the participation of two Glc residues in additional H-bonds with
distal amino acids of the protein (Glu242), whereas the inner
core is completely devoid of protein contacts.
Figure 13. Schematic cartoon of the Gram-positive bacterial cell wall
displaying WTA and LTA chains. The GalNAc-containing WTA structure is
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The liver and lymph node sinusoidal endothelial cell C-type
lectin (LSECtin) was described for the first time in 2004 by Liu
et al.[250] Its expression was initially described to be restricted to
liver and lymph node sinusoidal endothelial cells, although it
has also been found in Kupffer cells,[251] in ex vivo peripheral
blood, thymic DCs, and in monocyte-derived macrophages
in vitro.[252] Gramberg et al. found LSECtin tissue expression
limited to lymph node, liver, and also bone marrow
sinusoids.[253] The gene encoding LSECtin (CLEC4G) is located at
chromosome 19p13.3, a cluster that also contains sequences
codifying the closely related C-type lectins CD23, DC-SIGN and
DS-SIGNR. LSECtin is a type II trans-membrane protein, formed
by a short intracellular NH2-terminal tail of 31 amino acids, a
trans-membrane domain of 22 amino acids, and a long extra-
cellular domain (ECD). This ECD is composed by a neck region
of 110 residues and a C-type carbohydrate-recognition domain
(CRD) of 129 amino acids at the carboxyl terminus. From the
structural perspective, LSECtin was first detected in solution in
different oligomeric states from monomers to tetramers,[250]
with a molecular weight of 40 kDa for the monomeric unit.
Afterwards, it was observed the lectin mainly forms dimers (and
probably tetramers in small amount), through formation of
disulfide bonds using cysteine residues in the neck region.[254]
Analogously to other lectins of its gene cluster, LSECtin
possesses two N-glycosylation sites in the neck region at
positions 77 and 159.[250] Indeed, glycosylation was reported to
be a requirement for efficient expression on the cell surface.[255]
The intracellular Y6SKW and E14E motifs from the cytoplasmic
tail of the lectin have been related to ligand
internalization,[253,255] thus suggesting that the lectin might
promote the uptake of antigens in an immune response.
The biological role of LSECtin is rather diverse. A study in
mice with T-cell-mediated acute liver injury showed that
LSECtin is able to modulate hepatic T-cell activation. In
particular, the disease is accelerated in the absence of LSECtin,
leading to an increased immune response by T-cells. However,
the exogenous administration of recombinant LSECtin protein
or plasmid resulted in a protective effect and amelioration of
the damage by decreasing accumulation of T-cells, revealing its
possible therapeutic use for treatment of acute liver injury.[256]
LSECtin is expressed in human melanoma tissue, where it
facilitates tumor cells escape from the immune system by
inhibiting tumor-specific T-cell responses. The coregulatory
molecule LAG-3 on T-cells was identified as its binding
partner.[257] Moreover, LSECtin has also been found to be
involved in tumor progression in breast cancer.[258] Specifically,
it is highly expressed by tumor-associated macrophages in
human breast cancer tissue, where it is able to interact with the
breast cancer cell-intrinsic BTN3A3 receptor to promote tumor
stemness.
Regarding infections, LSECtin has reported to be an attach-
ment factor for the spike protein of the SARS coronavirus.[255]
The presence of GlcNAc terminating glycans in this glycoprotein
has been demonstrated, which is consistent with their recog-
nition by LSECtin.[254] For both SARS and Zaire Ebolavirus
(ZEBOV), LSECtin is able to enhance viral infection, in contrast
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to the observations for hepatitis C virus and HIV infection, even
though it is able to interact with the surface glycoprotein of the
latter.[255] Moreover, LSECtin delays the clearance of both
adenovirus and hepatitis B virus from blood and infected
hepatocytes.[259] In the case of a hepatotropic adenovirus, the
lack of LSECtin is translated in an increase of intrahepatic
effector CTLs, which generate cytokines and cytotoxic factors
with antiviral activity. In the case of hepatitis B virus, the
absence of LSECtin reduces the amount of hepatitis B virus-
specific IFN-γ-producing cells.
Additionally, it has been shown that LSECtin plays a key role
in the maintenance and regeneration of the intestinal epithelial
barrier during dextran sulfate sodium-induced colitis.[260] It was
found that LSECtin stimulated dead cell clearance phagocytosis
by macrophages, which at the same time makes the macro-
phages produce more tissue repairing factors, ultimately
promoting intestinal healing after damage. Furthermore, it has
been observed that LSECtin interacts, in cultured cells and brain
tissue in mice, with the β-site amyloid precursor protein
cleaving enzyme-1 (BACE1), a transmembrane protein crucial in
Alzheimer disease.[261] The lectin is able to negatively regulate
BACE1 function, which leads to a decrease in amyloid-β peptide
production. The results suggest that the interaction does not
take place through the bisecting GlcNAc residues on the
glycosylated enzyme, as initially hypothesized. Therefore,
further studies are necessary to unveil the mechanism of this
interaction.
In the molecular recognition context, LSECtin is able to bind
Man, Fuc, Glc, and GlcNAc in a calcium-dependent manner, as it
was shown by employing column-binding assays.[250] Binding to
Gal moieties was not observed. These experiments were
performed using a chimeric LSECtin fused to the Fc region of
human IgG1, LSECtin-Fc. Additionally, a sugar competition assay
showed that Man and GlcNAc were slightly tighter binders than
Fuc. Thus, these binding preferences strongly suggest that the
C3 and C4 hydroxy groups, oriented in an equatorial disposi-
tion, bind the Ca2+ ion at the lectin binding site in a similar
fashion of other CLRs. More recently, it has been observed that
neither Gal, GlcNAc, Fuc, nor Man, when incubated together
with LSECtin expressing cells infected with ZEBOV, were able to
block the interaction of the lectin with the virus
glycoproteins.[255] Nevertheless, the differences in the sugar
recognition profiles between these studies can be attributed to
the different experimental approaches employed. In fact, it has
been observed that there is not necessarily any correlation
between the capability of LSECtin to bind virus glycoproteins in
solution and its ability to effectively capture viral particles, as
described for HIV-1 virus.[253]
Mass spectrometry analysis on glycans released from the
viral glycoprotein GP1 of the Ebola virus surface suggest that N-
linked glycans carrying the GlcNAc residue at the terminal part
are responsible for LSECtin recognition.[254] In particular, by
employing glycan arrays, it was revealed that LSECtin preferen-
tially binds to GlcNAcβ1-2Man of terminal N-linked glycopro-
teins with high affinity and specificity.[254] A Kd of about 3.5 μM
was estimated for the disaccharide-lectin binding. More
recently, another glycan-array-based study revealed further
features on the recognition preferences of the lectin towards
branched N-glycans. In particular, the lectin prefers the
GlcNAcβ1-2Man epitope when presented at the 1–3 over its
presentation at the 1–6 branch, thus displaying an exquisite
branch specificity.[91]
6. Summary and Outlook
C-type lectin receptors (CLRs) are fundamental mediators in the
development of efficient immune responses. As highlighted
herein, they all are characterized by a very broad recognition
profile which can be finely tuned as the glycan complexity
increases. This is a particular feature of receptors from innate
leukocytes such as DCs and LCs, and improves their ability to
quickly detect a wide variety of strange substrates and initiate a
more specific adaptive response. However, the same feature
turns the quest for specific therapeutics into a challenging task.
Langerin and DC-SIGN are the paradigmatic cases of overlapped
specificities which lead to different outcomes: whereas Langerin
targets gp120 of HIV and promotes viral clearance, DC-SIGN
recognition results in efficient trans infection of T cells via DCs.
Interestingly, DC-SIGN exhibits a marked ligand promiscuity and
conversely, langerin stands out by its uncommon ability to
recognize sulfated glycans (GAGs). Thus, the inefficient recog-
nition of LeX by langerin could be used in favor of DC-SIGN
targeting, and similarly, GAGs can be exploited for modulation
of LC functions via langerin without affecting DCs. A rational
understanding about the structural features governing the fine
specificity in each case has been also proven to be effective for
achieving lectin specificity. Following this strategy, potent Man-
based compounds have resulted highly specific for DC-SIGN as
well.
MGL is involved in the recognition of tumor-related MUC1
variants, being a promising target for cancer therapy. In the last
years, important advances have been achieved concerning
those structural aspects underlying the recognition of GalNAc-
containing glycans, especially by NMR. The influence of
extended epitopes has set a solid basis to clarify the involve-
ment of certain TACAs in tumor surveillance via MGL. In this
regard, ligand presentation has been shown to influence the
ability of MGL to distinguish MUC1 variants according to their
glycosylation pattern and even the presence of neighboring
MUC1 amino acids. LSECtin might be another focus in cancer
therapy and disease progression. Its exquisite ability to target
the GlcNAcβ1-2Man disaccharide may be a starting point for
the design of specific substrates avoiding cross-reactivity with
DC-SIGN, for instance. However, it should be noted that, for
both MGL and LSECtin, more structural data is still needed to
delineate their respective sugar profiles, especially regarding
extended epitopes and multivalent scaffolds.
So far, the intrinsic geometry of CLRs notably has hampered
the rapid development of sugar mimetics with better affinities,
and multivalence has become a common solution to overcome
this fact. Importantly, lectin targeting at the cell membrane
must be thoroughly analyzed, as multivalent scaffolds provide
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taken into account, including ligand density and geometry.
Moreover, lectin specificity might be mandatory in certain cases,
whereas in other cases, as demonstrated, simultaneous CLR
targeting can result useful for achieving cell internalization and/
or stimulation of the desired immune response.
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